MedTrace Logo

Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

NCT06427668 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-08-17

No results posted yet for this study

Summary

This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.

Conditions

  • Alzheimer Disease

Interventions

DRUG

SPG302

synthetic small molecule

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Spinogenix

    lead INDUSTRY

Principal Investigators

  • Lauren Priest, MBBS · Flinders Medical Center, Adelaide, SA, Australia

  • Brew Brew, MBBS,MD,DSC · St Vincents Hospital, Sydney, NSW, Australia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-29
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06427668 on ClinicalTrials.gov